Praxis™ Extended RAS Panel
The Praxis™ Extended RAS Panel is an FDA approved, qualitative, in vitro diagnostic test for the detection of 56 specific mutations in RAS genes [KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4)] in colorectal cancer (CRC). These mutations are known to affect the efficacy of Vectibix (Panitumumab) for the treatment of metastatic colorectal cancer (mCRC). Vectibix is a monoclonal antibody directed against the epidermal growth factor receptor (EGFR). Although, monoclonal antibodies such as cetuximab and panitumumab, are used as a targeted therapy for CRC patients, these drugs are expensive and potentially toxic. Therefore, only patients who are likely to respond should be selected for antibody-based therapy to prevent unnecessary drug toxicity and associated expense.
Approximately 53% of patients with mCRC have RAS mutations, with 42.0% having KRAS exon 2 mutations and 11% having KRAS non-exon 2 and NRAS mutations. RAS mutations constitutively activate the RAS-RAF-ERK pathway and confer resistance to cetuximab and panitumumab. Therefore, patients whose tumors contain RAS mutations should not be treated with anti-EGFR mAbs.
- To detect RAS gene mutations in colorectal cancer and identify patients who are RAS mutation negative and therefore eligible for anti-EGFR mAB therapy
Negative:
no Praxis Extended RAS Panel mutations are detected.
Positive:
Praxis Extended RAS Panel mutation is detected (KRAS or NRAS gene)
Normal - no Praxis Extended RAS Panel mutations
Formalin fixed paraffin embedded (FFPE) tissue samples.
Stability
FFPE samples are stable at room temperature for longer.
- Oncotarget. 2017;8:3980-4000. [PMID: 28002810]
- World J Gastroenterol. 2012;18:5171-5180. [PMID: 23155342]
- BMC Res Notes. 2017;10:392. [PMID: 28797274]
- J Gastrointest Oncol. 2016;7: 687-704. [PMID: 27747083]
- PLoS One. 2019;14: e0226473. [PMID: 31881025]
- BMC Cancer. 2019;19: 640. [PMID: 31253124]
- J Gastrointest Oncol. 2015;6: 314-321. [PMID: 26029459]